Richard Conway RichardPAConway
3 years 10 months ago
Vural et al Rituximab biosimilar switch in GPA. Essentially it is the same. @RheumNow #ACR22 Abstr#1072 https://t.co/OBOMz35soX https://t.co/dPdcWQmBzd
Richard Conway RichardPAConway
3 years 10 months ago
Soussi et al. Over last 20 years, 5-year all-cause morality decreased in RA and controls in Danish study. But to greater extent in RA, narrowing mortality gap. @RheumNow #ACR22 Abstr#0711 https://t.co/JRh37u3uGm https://t.co/bA3Y5FLcRZ
Dr. Rachel Tate uptoTate
3 years 10 months ago
Have you heard of MyPROSLE (available at https://t.co/a4zlBtwaaC)? Abs 0329 details MyPROSLE's molecular characterization of individual SLE pts and it's extraction of key molecular information to support more precise therapeutic decisions. #ACR22 @RheumNow https://t.co/FslQCVvptw https://t.co/NNlgZvllPC
Patricia Harkins DrTrishHarkins
3 years 10 months ago
🔥ignite session🔥
❓Vessel wall MRI superior to TA-US in c-GCA❓
🔥In c-GCA vessel wall MRI examines beyond the temporal arteries -
✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures
Abst#0473
#ACR22 @RheumNow https://t.co/z8hYmqc95I
Richard Conway RichardPAConway
3 years 10 months ago
Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/Od1PXzJKQh https://t.co/Hk8mrblGMX
Eric Dein ericdeinmd
3 years 10 months ago
Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis
KEEPsAKE 1&2 - RZB v PBO
1407 pts -baseline 63% enth, 28% dact, 20% both
Wk 24: 14% decr. enthesitis, 17% decr dact, 13% decr both
Mean time to resolution decreased
Results maintained through wk 52
@RheumNow https://t.co/RBubeuJoh8
Richard Conway RichardPAConway
3 years 10 months ago
Frey @CaoilfhionnMD @JuliePaikMD et al. Increasing duration of hold of MMF (esp >=10 days) increased response to SARS-CoV-2 vaccine. No difference in disease flare rates. @RheumNow #ACR22 Abstr#0797 https://t.co/5nxo2nLg80 https://t.co/sx1Roxngx9
sheila RHEUMarampa
3 years 10 months ago
In this prospective cohort study by Dr Jacquez, there was a statistically significant inverse assoc bet. average yearly HCQ dose and overall damage accrual 👇
Reassuring data.
☝️HCQ consistently proves to be a beneficial drug for #lupus
#ACR22 @Rheumnow ABST#0982 @rheumarhyme https://t.co/nWHS9JtEsH
Richard Conway RichardPAConway
3 years 10 months ago
Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after completion. Cited reasons: ongoing preparation/review of paper (50%), sponsor/funder problems (40%), unimportant/negative result (20%).@RheumNow #ACR22 Abstr#0827 https://t.co/V2a48iiAcn https://t.co/FLqQhjvlOx
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR22 Abstr#0825 Can we identify predictors of deaths in patients presenting with Macrophage Activation Syndrome? A cohort study (N=43) reported MAS was mostly secondary to disease. 10/43 died. Super high Ferritin and raised Ferritin/CRP ratio were assoc with deaths @RheumNow https://t.co/JCH30pi4Vf
The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
Once in a while, I find an abstract at the ACR meeting that can potentially save lives and be implemented in practice now.
In Abstract #0939, Dr. J Patricia Dhar and colleagues shared data from a pilot study examining a new method to monitor cervical health in African American Women with Systemic Lupus Erythematosus (SLE) using a self-sampling brush to assess cervical cytology and human papilloma virus infection.
Richard Conway RichardPAConway
3 years 10 months ago
Boekel et al. Omicron variant assoc lower risk of severe COVID-19 in rheumatic disease than prior variants EXCEPT rituximab treated patients. @RheumNow #ACR22 Abstr#0705 https://t.co/57Boj4SEt5 https://t.co/d2NoX83y5l
Richard Conway RichardPAConway
3 years 10 months ago
Mendel et al. Use of TMP-SMX prophylaxis in GPA from MarketScan and Medicaid. Used in <25% treated with RTX!? Female sex negatively assoc (OR 0.61)!? Steroid use in month prior associated (OR 4.31) @RheumNow #ACR22 Abstr#1071 https://t.co/56a0nHR8o4 https://t.co/5LygdFMrss
Richard Conway RichardPAConway
3 years 10 months ago
Kifayat et al. Response to Shingrix in rheumatic disease patients. 3/3 PsA, 5/6 SLE, 2/14 RA pts reached protective level of 150U/ml. IgG titres and SI are 3x lower compared to non-rheumatic patients. @RheumNow #ACR22 Abstr#0800 https://t.co/Gm7ldxK5xd https://t.co/BlHuU2Jxk2

